SCHEMBL9063201

SCHEMBL9063201

CCCC(=N)NC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9063292 0.82
SCHEMBL9062428 0.80
SCHEMBL11588702 0.78 SPHK2 (0.52)
SCHEMBL11590254 0.78 SPHK2 (0.52)
SCHEMBL9062425 0.78 SPHK2 (0.52)
SCHEMBL19197699 0.78 SPHK2 (0.52)
SCHEMBL640653 0.75
SCHEMBL3808409 0.75
SCHEMBL24933469 0.75 HSD17B10 (0.33)
SCHEMBL1938703 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0531219-B1 Use of histamine derivatives for the preparation of drugs, new histamine derivatives and drugs BIOPROJET SOC CIV (FR) 1995-12-06 EP claimed
EP-0385038-B1 ORTHO-SUBSTITUTED PHENYL AMIDINE AND PHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM The Boots Company PLC (GB) 1993-06-02 EP claimed
EP-0385038-A1 Ortho-substituted phenyl amidine and phenyl guanidine derivatives and antidiabetic or hypoglycaemic agents containing them The Boots Company PLC (GB) 1990-09-05 EP claimed
CN-113365627-A VDAC inhibitors for the treatment of inflammatory bowel disease 国家生物技术研究所公司 2021-09-07 CN disclosed
CN-113347973-A VDAC inhibitors for the treatment of autoimmune diseases 国家生物技术研究所公司 2021-09-03 CN disclosed
WO-2021158481-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2021-08-12 WO disclosed
WO-2020247546-A1 ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE BIOINTERVENE, INC. (US) 2020-12-10 WO disclosed
US-8093258-B2 Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases WILEX AG (DE) 2012-01-10 US disclosed
US-20100222380-A1 Modified Chalcone Compounds as Antimitotic Agents ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) 2010-09-02 US disclosed
US-7714025-B2 Modified chalcone compounds as antimitotic agents ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) 2010-05-11 US disclosed
US-20090069251-A1 Use Of Urokinase Inhibitors for the Treatment and/or Prevention of Neuropathological Diseases WILEX AG (DE) 2009-03-12 US disclosed
US-20070265317-A1 MODIFIED CHALCONE COMPOUNDS AS ANTIMITOTIC AGENTS ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) 2007-11-15 US disclosed
EP-1644343-B1 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-07-04 EP disclosed
WO-1996017612-A1 USE OF SUBSTITUTED PHENYLAMIDINE AND PHENYLGUANIDINE COMPOUNDS FOR THE TREATMENT OF CEREBRAL AND CARDIAC ISCHAEMIA, CONVULSION AND SICKLE CELL ANAEMIA KNOLL AKTIENGESELLSCHAFT (DE) 1996-06-13 WO disclosed
EP-0531219-B1 Use of histamine derivatives for the preparation of drugs, new histamine derivatives and drugs BIOPROJET SOC CIV (FR) 1995-12-06 EP disclosed
US-5373008-A Phenylamidine and phenylguanidine derivatives and their use as anti-diabetic agents THE BOOTS COMPANT PLC. (GB) 1994-12-13 US disclosed
US-5223498-A Hypoglycemic agents THE BOOTS COMPANY PLC (GB) 1993-06-29 US disclosed
EP-0385038-B1 ORTHO-SUBSTITUTED PHENYL AMIDINE AND PHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM The Boots Company PLC (GB) 1993-06-02 EP disclosed
EP-0385038-A1 Ortho-substituted phenyl amidine and phenyl guanidine derivatives and antidiabetic or hypoglycaemic agents containing them The Boots Company PLC (GB) 1990-09-05 EP disclosed